Literature DB >> 11573992

Subthalamic nucleus lesions are neuroprotective against terminal 6-OHDA-induced striatal lesions and restore postural balancing reactions.

G A Carvalho1, G Nikkhah.   

Abstract

Inactivation of the subthalamic nucleus (STN) by deep brain stimulation or lesioning can ameliorate symptoms in Parkinson' disease (PD) and may alter the underlying progressive degenerative process. We evaluated the effects of STN lesions in a terminal lesion model of PD in rats. Multiple intrastriatal 6-OHDA injections (4 x 7 microg) resulted in a partial loss of striatal TH-positive innervation (-30 to -40%) and nigral dopaminergic neurons (-60%), which was associated with behavioral deficits as observed in drug-induced rotational asymmetry, side-stepping, and postural balancing reactions. Unilateral ibotenic acid lesions of the STN did produce a 50-60% loss of STN neurons based on stereological analysis, which did not induce a functional impairment in rotational asymmetry or spontaneous sensorimotor behaviors. When STN lesions were performed 1 week prior to the 6-OHDA terminal striatal lesions, a significant rescue effect (+23%) on nigral dopaminergic neurons against terminal 6-OHDA neurotoxicity could be demonstrated, whereas striatal TH-positive fiber loss was not attenuated in these animals. In addition, animals with combined STN and striatal lesions exhibited a significant recovery in postural balancing reactions induced by 6-OHDA terminal lesions and did not show a significant impairment in any of the other behavioral parameters examined. Taken together, STN lesions can exert neuroprotective effects on nigral dopamine neurons in a partial lesion model of PD which result in recovery of spontaneous sensorimotor behavior. These findings may therefore provide new insights into the functional interaction between the glutamatergic and the dopaminergic neurotransmitter systems and foster novel therapeutic concepts for the early and middle phases of Parkinson's disease. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11573992     DOI: 10.1006/exnr.2001.7742

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  13 in total

1.  The artificial silicon retina in retinitis pigmentosa patients (an American Ophthalmological Association thesis).

Authors:  Alan Y Chow; Ava K Bittner; Machelle T Pardue
Journal:  Trans Am Ophthalmol Soc       Date:  2010-12

Review 2.  Basal ganglia, movement disorders and deep brain stimulation: advances made through non-human primate research.

Authors:  Thomas Wichmann; Hagai Bergman; Mahlon R DeLong
Journal:  J Neural Transm (Vienna)       Date:  2017-06-10       Impact factor: 3.575

3.  Dopamine transporter imaging and the effects of deep brain stimulation in patients with Parkinson's disease.

Authors:  A Lokkegaard; L M Werdelin; L Regeur; M Karlsborg; S R Jensen; E Brødsgaard; F F Madsen; M N Lonsdale; L Friberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-11-10       Impact factor: 9.236

Review 4.  Glutamate receptors as therapeutic targets for Parkinson's disease.

Authors:  Kari A Johnson; P Jeffrey Conn; Colleen M Niswender
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

5.  Neuronal activity in the subthalamic nucleus modulates the release of dopamine in the monkey striatum.

Authors:  Yasushi Shimo; Thomas Wichmann
Journal:  Eur J Neurosci       Date:  2008-12-12       Impact factor: 3.386

6.  Altered nucleolar morphology in substantia nigra dopamine neurons following 6-hydroxydopamine lesion in rats.

Authors:  Michelle Healy-Stoffel; S Omar Ahmad; John A Stanford; Beth Levant
Journal:  Neurosci Lett       Date:  2013-05-02       Impact factor: 3.046

7.  A novel use of combined tyrosine hydroxylase and silver nucleolar staining to determine the effects of a unilateral intrastriatal 6-hydroxydopamine lesion in the substantia nigra: a stereological study.

Authors:  Michelle Healy-Stoffel; S Omar Ahmad; John A Stanford; Beth Levant
Journal:  J Neurosci Methods       Date:  2012-07-28       Impact factor: 2.390

8.  Subthalamic nucleus deep brain stimulation for Parkinson's disease: 8 years of follow-up.

Authors:  Dianyou Li; Chunyan Cao; Jing Zhang; Shikun Zhan; Shengdi Chen; Bomin Sun
Journal:  Transl Neurodegener       Date:  2013-05-24       Impact factor: 8.014

9.  Subthalamic nucleus deep brain stimulation in elderly patients--analysis of outcome and complications.

Authors:  Jan Vesper; Susanne Haak; Christoph Ostertag; Guido Nikkhah
Journal:  BMC Neurol       Date:  2007-03-16       Impact factor: 2.474

10.  Timing of deep brain stimulation in Parkinson disease: a need for reappraisal?

Authors:  Ruth-Mary deSouza; Elena Moro; Anthony E Lang; Anthony H V Schapira
Journal:  Ann Neurol       Date:  2013-05       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.